

## BROLUCIZUMAB solution for injection (Beovu® ▼) for treating wet age-related macular degeneration

**The Pan Mersey Area Prescribing Committee recommends the prescribing of BROLUCIZUMAB solution for injection (Beovu® ▼), by specialists only for treating wet age-related macular degeneration in line with NICE TA672.**

**RED**

[NICE technology appraisal \(TA\) 672](#)<sup>1</sup> (03 February 2021) recommends brolocizumab as an option for treating wet age-related macular degeneration (wAMD) in adults, only if, in the eye to be treated:

- > the best-corrected visual acuity is between 6/12 and 6/96
- > there is no permanent structural damage to the central fovea
- > the lesion size is less than or equal to 12 disc areas in greatest linear dimension **and**
- > there is recent presumed disease progression (for example, blood vessel growth, as shown by fluorescein angiography, or recent visual acuity changes).

It is recommended only if the company provides brolocizumab according to the commercial arrangement.

If patients and their clinicians consider brolocizumab to be one of a range of suitable treatments, including aflibercept and ranibizumab, choose the least expensive (taking into account administration costs and commercial arrangements).

Only continue brolocizumab in people who maintain an adequate response to therapy. Criteria for stopping should include persistent deterioration in visual acuity and identification of anatomical changes in the retina that indicate inadequate response to therapy.

### Cost Comparison Results

- > The overall health benefits of brolocizumab are similar to those of aflibercept and ranibizumab.
- > When taking account of the confidential commercial discounts for all treatments, the total costs (including administration) associated with brolocizumab are similar to or lower than those of aflibercept and ranibizumab.
- > This assumes comparator injection numbers in year 1 and 2 based on TRES regimen estimates, and injection numbers in year 3 and beyond is equivalent for all treatments and based on estimates from [NICE TA294](#).
- > NICE concluded that brolocizumab is a cost effective use of NHS resource for treating wAMD in adults.

### References

1. National Institute for Health and Care Excellence. Technology Appraisal 672: [Brolocizumab for treating wet age-related macular degeneration](#); 03 February 2021. Accessed online 09 February 2021.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.